Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
10th AGM, BGS Cardiovascular Section, London - July ‘10 Arrhythmias in the elderly Something old, something new? John P. Bourke Consultant & Senior Lecturer in Cardiology Freeman Hospital Arrhythmias in the elderly ◊ Changing aetiology of arrhythmias with age ◊ Congenital arrhythmias still present .... ◊ Update on atrial fibrillation management ◊ Ventricular tachy-arrhythmias in the elderly ◊ Device therapy dilemmas in the elderly Aetiology of Arrhythmias by Age Congenital or Acquired Younger Middle-aged Brady- or Tachycardias Elderly Congenital Arrhythmias in the Elderly ...?! • Those that have been putting up with SVTs for years • Increasing SVT frequency due to increased ectopy despite drugs • Emergence of pre-excitation due to AV-nodal disease or medications • • • • Catheter ablation equally applicable with 95% success rates SVT with BBB commoner & may complicate diagnosis AV-nodal modification (AVJRT) carries higher risk of AV-block WPW as bystander to acquired atrial tachy-arrhythmias – SVT stops with CSM / Adenosine is the key to Dx – - SVT returns > 2 yrs after successful ablation = different arrhythmia - Mrs DMcD – Aged 88 yrs • Long history of narrow QRS tachycardias 1. Good example of amiodarone’s long-term toxicity profile • Infrequent episodes since started typical amiodarone early 1990s – Became hypothyroid 1998 – Amiodarone discontinued & EP / Ablation recommended 2. Complicating effect of amiodarone on diagnosis & ablation • EP-study 1998 (shortly after amiodarone withdrawal) – aged 76 yrs – all conduction very sluggish – no inducible arrhythmias & arrhythmia substrate indeterminate (? atrial tachycardia) 3. SVT-ablation’s success is not age dependent • EP-repeat study 2010 – Concealed accessory pathway confirmed with AV-reentrant SVT – Ablation of left free wall pathway with single lesion Acquired Arrhythmias 10 Electrical - Age-related AF / A-flutter - Tachy-brady syndrome (Sinus node Ds) 20 to Structural Disease - Hypertensive heart Ds - Post-infarction / Cardiomyopathy - Valve disease (eg: MR or AR) Atrial Fibrillation & Ventricular Tachycardia Atrial Fibrillation a degenerative conditon of ‘old age’ (?) Complex patient-pathways in Atrial Fibrillation About 50% patients with AF are diagnosed in 10 care & 20% remain there for management 44% diagnosed in primary care Primary Care 20% remain in primary care 28% Diagnosis 9% A&E/MAU Cardiology 18% Other Spec. 68% referred to cardiology 40% Primary Care 25% 34% Cardiology 90% referred to primary care for management CoE/GenMed Other Spec. 65% 26% AF=atrial fibrillation; A&E=accident and emergency; MAU=medical assessment unit; CoE=care of the elderly; GenMed=general medical “Atrial fibrillation begets atrial fibrillation” Sinus Rhythm Eroding anti-AF threshold Paroxysmal AF Evolving Triggers & substrates Cardioversion Persistent AF Secondary electrical changes More frequent / longer episodes Permanent AF Secondary electrical changes Secondary structural changes No longer able to restore / maintain SR When is it pointless to call the fire brigade? Rhythm control management cannot be an afterthought …! Challenge of deploying newer therapies optimally Equality of access to treatment options..? • Anti-arrhythmic management – Dronedarone / Vernakalant – Pacing & AV-nodal ablation – Catheter ablation • Stroke Prevention - Warfarin vs Dabigatran - Left atrial occlusion devices • Newer options in valve disease - Mitral valve clips for MR - TAVI for AS - Timing of surgical MVR DDDRP AFFIRM STUDY Inclusion Age > 65 or 1 major risk factor for death or stroke AF – The rhythm versus rate control debate % pts in SR at study end Does this mean sinus rhythm & AF equivalent? 62.6 NO ! 34.6 38.7 38 rhythm control rate control • Recruited only mildly symptomatic pts, who could be randomized to either strategy •Success of rhythm control poor with AA Rx 10 9 RACE STAF • Survival benefits offset by effects of AADs • Spontaneous reversion to SR high AFFIRM ◊ Presence of AF was associated with worse NYHA-FC (p < 0.0001) ◊ Improved in 6-minute walk test in rhythm control group (p = 0.049) Effect of rate & rhythm control on left ventricular function & cardiac dimensions in patients with persistent atrial fibrillation: RACE Study Echo study with deterioration 1-2 year follow-up (N = 335) ◊ Routine rate control prevents of LV-function. In rhythm control group LV-function compared between SR & AF pts at study end ◊ Maintenance of sinus rhythm improves LV-function & reduces atrial sizes Hagens et al. Heart Rhythm 2005, 2:19-24 Circulation 2004, 109:1509-15 ◊ Variables associated with increased risk of death - Increasing age - Coronary artery disease - Congestive cardiac failure; Left ventricular dysfunction - Diabetes mellitus or smoking - Stroke or TIA - Mitral regurgitation ◊ Variables associated with reduced risk of death - Maintenance or sinus rhythm - Warfarin therapy ◊ Anti-arrhythmic drugs ≠ improved survival - any benefits are offset by adverse effects AHA Guidelines 2006 Dronedarone & atrial-selective anti-arrhythmic agents (?) Dronedarone Vernakalant (acute cardioversion) Atrially-selective anti-arrhythmic agent(s) Vernakalant • Atrially-selective potassium channel blocker with short half life • Reduced risk of pro-arrhythmia & negative inotropic effects • Currently an iv drug for acute cardioversion of recent onset AF • Oral version likely to follow for maintenance of SR May reduce the threshold for attempted cardioversion in borderline cases (no GA or sedation required; ‘less inconvenient’) Non-pharmacological therapies for AF in the elderly .....? AHA Guidelines 2006 Outcome of AF ablation - randomized comparison of ablation vs drugs Pappone APAF JACC Oct 06 NavX-guided point-by-point isolation of pulmonary veins & ‘roof line’ LA & Pulmonary Veins Ablation lesion Radiofrequency catheter ablation of AF in older patients Outcomes & Complications N = 240 < 65 years 65-75 years > 75 years p 91 88 61 --- Persistent AF 24% 34% 66%* < 0.01 Major complications 1% 1% 0% NS Minor complications 4% 5% 5% NS SR without AARx 94%* 84% 61% < 0.01 Hospital attendances Pre- vs Post-ablation 22 / 3 26 / 4 20 / 2 < 0.01 N Patients > 75 years: AF < 1 hour + AARx = 82% Selection criteria for catheter ablation of AF • Technically it can be preformed in almost anyone .... but it’s primarily indicated for symptom control not for prognosis! • Best results - No structural heart disease & paroxysmal AF Serious complications = 1-2% per procedure Success = 85% with 1-2 procedures • Less predictable results – persistent AF & dilated LA / LVH Success = 70% with 1-2 procedures • Research procedures – paroxysmal or persistent AF in CCF / HCM or chronic persistent AF (> 12 mths) 82 yrs old female presents to A&E • Sustained palpitations for several hours Anxious but stable; ECG confirms AF; ventricular rate = 110 / min She is on no cardio-active medications • Increasingly frequent similar episodes x 14 months, lasting < 4 hours Episodes tend to start when she is at rest or even asleep. • Recently, feels faint as palpitations terminate with two falls resulting 2.4 sec 5.4 sec pause post-AF Low Heart Rate Variability = SSS & AF AF in tachy-brady syndrome likely to be abolished by atrial pacing Atria Correct sinus node Ds & restore chronotropic competence + DDDRP Ventricles To allow anti-arrhythmic drugs to control tachycardia Arrhythmias in the elderly ◊ Changing aetiology of arrhythmias with age ◊ Congenital arrhythmias still present .... ◊ Update on atrial fibrillation management ◊ Ventricular tachy-arrhythmias in the elderly ◊ Device therapy dilemmas in the elderly Ventricular Tachy-arrhythmias in the elderly A Matter of Life or Death The same arrhythmia – very different management ... !? 1. Why did it happen ? 2. Will it recur ? 3. Does it require post-acute management ? 4. Does it require specific anti-arrhythmic management ? Remote MI Poor LV function Acute ischaemia / MI Drug induced Biochemical upset Highly likely to recur! ... ‘One-off’ event? Commonest cause of VT is old myocardial infarction ■ 72 yr old male ■ PHx: inferior MI (1989) ■ CABG x 4 (1990) ■ LVEF = 32% ■ Rx: bisoprolol, ramipril, simvastatin, aspirin Commonest cause of VT is old myocardial infarction Progressive LV-dysfunction Renewed coronary ischaemia As well as the arrhythmia recurrences ... If ‘high risk’ of arrhythmia recurrence ... AVID Study AVID Trial (2ndry prevention) ‘ ... Among survivors of VF or sustained VT, causing severe P < 0.02 symptoms, the ICD is superior to anti-arrhythmic drugs for increasing overall survival ...’ N Engl J Med 1997, 337:1576-83. Mrs WJ - 78 yrs ■ Jan ‘10: OPD referral - ‘Palpitations’ / No LOC or compromise - Uncomplicated anterior MI (2008) - Examination: No abnormalities - Hx suggestive of isolated ectopic beats ■ Other: ACEi, BB, statin & aspirin therapy Ex-smoker (10 / day) Normotensive No DM Mrs WJ - 78 yrs Mrs WJ - 78 yrs ■ Investigations Holter ECG Non-sustained VT (8 bts / 200 bpm) – symptoms (+) Echo Large anterior LV-akinetic segment (LVEF 34%) Cor angios No obstructive coronary lesions Ms WJ - EP-Testing: Is she capable of sustained VT? 2 extras Sustained VT RV Drive Mrs WJ - 78 yr - VT induce in EP-Lab VT CL = 230ms (260 bpm) MADIT I Trial Primary Prevention LVEF < 35% & NSVT & inducible VT MADIT I Trial EP-testing(+) ‘ ... In patients with prior MI, who are at high risk of VT / VF, prophylactic therapy p = 0.009 with an ICD leads to improved survival compared to conventional medical therapy’ N Engl J Med 1996, 335:1933-40 Mr RL - 80 yrs ■ Aug ‘09: Admitted to DGH after collapse & spontaneous recovery Also several previous ‘dizzy spells’ ■ PHx: Ischaemic heart Ds Previous anterior MI LBBB on ECG (QRS = 120 ms) LVEF < 30% ■ Rx: lisinopril, metoprolol, furosemide, L-thyroxine, allopurinol MADIT II Trial Primary Prevention LVEF < 35% & NSVT alone MADIT II Trial (No EP testing) ‘ ... In patients with prior MI & advanced LV-dysfunction, P = 0.007 prophylactic ICD implantation improves survival and should be considered as a recommended therapy‘ N Engl J Med 2002, 346:877-83 Total Mortality Benefits - NNTT ♥ Combining all trials (10 & 20 prevention; Post MI & DCM) (1 death Most of theNNTT benefit .... in 2 years) = 13 Patients with CADs, LV-dysfunction & inducible VT at risk EP study But depends on baseline ♥Less If primary prevention benefit ... with post-infarction & LVEF < 30% NNTT (1 death over 2 yrs) Moderate risk group or CABG or DCM = 18 ♥ If same background & inducible VT NNTT (1 death over 2 yrs) = 4 Pacing to improve coordination of cardiac contraction (atrio-ventricular; inter- & intra-ventricular resynchronisation) Pacing to improve LV-function RA LV RVA Electrical resynchronization Cardiac resynchronisation therapy + ICD component 1 CRT & CRTD 3 2 MADIT-CRT Trial To assess whether CRT-D reduces mortality & heart failure events in patients with: NYHA class I-II QRS > 130ms LVEF < 30% ■ 34% reduced all-cause mortality or 1st heart failure event with CRT-D (p < 0.001) ■ 41% reduction in HF events (p < 0.001) ■ Benefits IHD = DCM p < 0.001 Arrhythmias in the elderly ◊ Changing aetiology of arrhythmias with age ◊ Congenital arrhythmias still present .... ◊ Update on atrial fibrillation management ◊ Ventricular tachy-arrhythmias in the elderly ◊ Device therapy dilemmas in the elderly A simple scenario ..? ◊ 79 yr old lady referred with symptomatic CHB of recent onset ◊ Asymptomatic coronary Ds (ie: no active ischaemia) & previous LBBB ◊ Old inferior MI, LVEF 25% & NYHA II dyspnoea ◊ Recent drug therapy: ACEi, Beta-blocker, Statin, Aspirin & Furosemide Requires permanent pacing Made unnecessarily complex ....??? What is her most appropriate therapy? Standard Pacemaker (2-leads) Resynchronisation Pacemaker (3-leads) Combined Resynchronisation Pacing & Defibrillator Arrhythmias in the elderly ◊ Changing aetiology of arrhythmias with age ◊ Congenital arrhythmias still present .... ◊ Update on atrial fibrillation management ◊ Device therapy dilemmas in the elderly